STADA Arzneimittel AG (ETR:SAZ) received a €66.25 ($78.87) price target from equities research analysts at Warburg Research in a research note issued to investors on Wednesday. The firm currently has a “sell” rating on the stock.

Several other brokerages also recently issued reports on SAZ. Commerzbank Ag set a €66.00 ($78.57) price target on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Monday, July 3rd. S&P Global set a €63.00 ($75.00) price target on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Wednesday, June 28th. Kepler Capital Markets set a €58.00 ($69.05) price target on shares of STADA Arzneimittel AG and gave the stock a “sell” rating in a report on Wednesday, June 28th. Finally, Independent Research GmbH set a €50.00 ($59.52) price target on shares of STADA Arzneimittel AG and gave the stock a “sell” rating in a report on Tuesday, June 27th. Three research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. STADA Arzneimittel AG presently has a consensus rating of “Sell” and an average target price of €68.15 ($81.13).

STADA Arzneimittel AG (ETR:SAZ) opened at 78.615 on Wednesday. STADA Arzneimittel AG has a 12 month low of €41.40 and a 12 month high of €84.20. The firm has a market cap of €4.89 billion and a price-to-earnings ratio of 51.960. The firm’s 50-day moving average price is €67.15 and its 200-day moving average price is €62.43.

TRADEMARK VIOLATION NOTICE: “Warburg Research Analysts Give STADA Arzneimittel AG (SAZ) a €66.25 Price Target” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/warburg-research-analysts-give-stada-arzneimittel-ag-saz-a-66-25-price-target/1531236.html.

About STADA Arzneimittel AG

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel AG (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with Analyst Ratings Network's FREE daily email newsletter.